公开(公告)号：US08940272B2

公开(公告)日：2015-01-27

申请号：US13271118

申请日：2011-10-11

申请人： Roger Nitsch ,  Feng Chen ,  Jan Grimm ,  Jean-Luc Baeriswyl ,  Christoph Hock

发明人： Roger Nitsch ,  Feng Chen ,  Jan Grimm ,  Jean-Luc Baeriswyl ,  Christoph Hock

IPC分类号： A61K39/395 ,  C12P21/08 ,  C07K16/18 ,  C07K14/47 ,  G01N33/68

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K2039/505 ,  C07K14/47 ,  C07K14/4711 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/90 ,  C07K2317/92 ,  G01N33/6896 ,  G01N2333/47 ,  G01N2800/56

摘要： Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

摘要翻译： 提供新的人tau特异性抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与特异于tau的抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可分别用于tau靶向免疫治疗和诊断的药物和诊断组合物中。

公开(公告)号：US20130295021A1

公开(公告)日：2013-11-07

申请号：US13878839

申请日：2011-10-11

申请人： Feng Chen ,  Jan Grimm ,  Jean-Luc Baeriswyl ,  Roger Nitsch ,  Christoph Hock

发明人： Feng Chen ,  Jan Grimm ,  Jean-Luc Baeriswyl ,  Roger Nitsch ,  Christoph Hock

IPC分类号： C07K16/18 ,  G01N33/68 ,  C07K14/47 ,  A61K39/395

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K2039/505 ,  C07K14/47 ,  C07K14/4711 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/90 ,  C07K2317/92 ,  G01N33/6896 ,  G01N2333/47 ,  G01N2800/56

摘要： Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

摘要翻译： 提供人tau特异性抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与特异于tau的抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可分别用于tau靶向免疫治疗和诊断的药物和诊断组合物中。

公开(公告)号：US20120087861A1

公开(公告)日：2012-04-12

申请号：US13271118

申请日：2011-10-11

申请人： Roger Nitsch ,  Feng Chen ,  Jan Grimm ,  Jean-Luc Baeriswyl ,  Christoph Hock

发明人： Roger Nitsch ,  Feng Chen ,  Jan Grimm ,  Jean-Luc Baeriswyl ,  Christoph Hock

IPC分类号： A61K51/10 ,  C12N15/13 ,  C12N15/63 ,  C12N1/21 ,  C12N1/19 ,  C12N5/10 ,  C12P21/08 ,  C12N9/96 ,  A61K39/395 ,  C40B30/04 ,  G01N33/566 ,  A61K49/16 ,  A61K49/00 ,  A61P25/28 ,  A61P25/16 ,  A61P25/00 ,  C07K16/18

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K2039/505 ,  C07K14/47 ,  C07K14/4711 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/90 ,  C07K2317/92 ,  G01N33/6896 ,  G01N2333/47 ,  G01N2800/56

摘要： Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

摘要翻译： 提供新的人tau特异性抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与特异于tau的抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可分别用于tau靶向免疫治疗和诊断的药物和诊断组合物中。

公开(公告)号：US20100172919A1

公开(公告)日：2010-07-08

申请号：US12664540

申请日：2008-06-16

申请人： Jan Grimm ,  Roger Nitsch ,  Feng Chen

发明人： Jan Grimm ,  Roger Nitsch ,  Feng Chen

IPC分类号： A61K38/18 ,  C07K14/505 ,  A61K39/395 ,  A61P25/28 ,  G01N33/68

CPC分类号： A61K38/1816

摘要： Provided are novel drugs and methods in the treatment as well as diagnosis of neurological disorders such as Alzheimer's disease and amyloid-beta pathology/amyloidosis. More specifically, the use of erythropoietin and analogs thereof for the treatment of Aβ peptide related brain impairments is described. Furthermore, the use of claudin-5 and variants thereof as biomarker for Alzheimer's disease and for the progression of Alzheimer's disease, respectively, is provided.

摘要翻译： 提供了治疗中的新型药物和方法以及诸如阿尔茨海默病和淀粉样蛋白β病理学/淀粉样变性之类的神经障碍的诊断。 更具体地，促红细胞生成素及其类似物用于治疗A＆bgr; 描述了肽相关的脑损伤。 此外，提供了分别使用claudin-5及其变体作为阿尔茨海默病的生物标志物和阿尔茨海默氏病的进展。

公开(公告)号：US20080261878A1

公开(公告)日：2008-10-23

申请号：US11976318

申请日：2007-10-23

申请人： Jurgen Gotz ,  Roger Nitsch ,  Feng Chen

发明人： Jurgen Gotz ,  Roger Nitsch ,  Feng Chen

IPC分类号： A61K38/00 ,  A61P25/00

CPC分类号： C07K14/4711 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0312 ,  A01K2267/0318 ,  C12N15/8509

摘要： The present invention discloses a method and an in-vivo assay system useful for the identification and testing of modulating agents as well as for the validation of therapies of neurodegenerative diseases associated with the formation of neurofibrillary tangles, in particular Alzheimer's disease. The present invention is based on the surprising-finding that injection of β-amyloid Aβ42 fibrils into brains of P301L mutant tau transgenic mice caused several-fold increases in the numbers and an accelerated production of neurofibrillary tangles in cell bodies predominantly within the amygdala. The induced neurofibrillary tangles occurred as early as 18 days after Aβ42 injections and displayed striking features of neurofibrillary tangles of several human neurodegenerative diseases, particularly Alzheimer's disease.

摘要翻译： 本发明公开了一种可用于鉴定和测试调节剂的方法和体内测定系统，以及用于验证与形成神经原纤维缠结，特别是阿尔茨海默病有关的神经变性疾病的疗法。 本发明基于令人惊奇的发现，即将β-淀粉样蛋白Aβ2-2原纤维注射到P301L突变体tau转基因小鼠的脑中导致数量增加数倍，并且加速了神经原纤维缠结的产生 细胞体主要位于杏仁核内。 诱导的神经原纤维缠结发生早于Abeta 42注射后18天，并显示几种人类神经变性疾病，特别是阿尔茨海默病的神经原纤维缠结的显着特征。

公开(公告)号：US20050015819A1

公开(公告)日：2005-01-20

申请号：US10487546

申请日：2002-08-24

申请人： Jurgen Gotz ,  Roger Nitsch ,  Feng Chen

发明人： Jurgen Gotz ,  Roger Nitsch ,  Feng Chen

IPC分类号： A01K67/027 ,  C07K14/47 ,  C12N15/09 ,  C12N15/85 ,  C12N15/00

CPC分类号： C07K14/4711 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0312 ,  A01K2267/0318 ,  C12N15/8509

摘要： The present invention discloses a method and an in-vivo assay system useful for the identification and testing of modulating agents as well as for the validation of therapies of neurodegenerative diseases associated with the formation of neurofibrillary tangles, in particular Alzheimer's disease. The present invention is based on the surprising finding that injection of β-amyloid Aβ42 fibrils into brains of P301L mutant tau transgenic mice caused several-fold increases in the numbers and an accelerated production of neurofibrillary tangles in cell bodies predominantly within the amygdala. The induced neurofibrillary tangles occurred as early as 18 days after Aβ42 injections and displayed striking features of neurofibrillary tangles of several human neurodegenerative diseases, particularly Alzheimer's disease.

摘要翻译： 本发明公开了一种可用于鉴定和测试调节剂的方法和体内测定系统，以及用于验证与形成神经原纤维缠结，特别是阿尔茨海默病有关的神经变性疾病的疗法。 本发明基于惊人的发现，即将β-淀粉状蛋白Aβ42原纤维注射到P301L突变体tau转基因小鼠的脑中，导致数量增加了数倍，并且主要在杏仁核内的细胞体中加速了神经原纤维缠结的产生。 诱导的神经原纤维缠结发生早于Abeta42注射后18天，并显示出几种人类神经变性疾病，特别是阿尔茨海默病的神经原纤维缠结的显着特征。

公开(公告)号：US07550648B2

公开(公告)日：2009-06-23

申请号：US11976318

申请日：2007-10-23

申请人： Jürgen Götz ,  Roger Nitsch ,  Feng Chen

发明人： Jürgen Götz ,  Roger Nitsch ,  Feng Chen

IPC分类号： G01N33/00 ,  A01K67/033

CPC分类号： C07K14/4711 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0312 ,  A01K2267/0318 ,  C12N15/8509

摘要： The present invention discloses a method and an in-vivo assay system useful for the identification and testing of modulating agents as well as for the validation of therapies of neurodegenerative diseases associated with the formation of neurofibrillary tangles, in particular Alzheimer's disease. The present invention is based on the surprising finding that injection of β-amyloid Aβ42 fibrils into brains of P301L mutant tau transgenic mice caused several-fold increases in the numbers and an accelerated production of neurofibrillary tangles in cell bodies predominantly within the amygdala. The induced neurofibrillary tangles occurred as early as 18 days after Aβ42 injections and displayed striking features of neurofibrillary tangles of several human neurodegenerative diseases, particularly Alzheimer's disease.

摘要翻译： 本发明公开了一种可用于鉴定和测试调节剂的方法和体内测定系统，以及用于验证与形成神经原纤维缠结，特别是阿尔茨海默病有关的神经变性疾病的疗法。 本发明基于惊人的发现，即将β-淀粉状蛋白Aβ42原纤维注射到P301L突变体tau转基因小鼠的脑中，导致数量增加了数倍，并且主要在杏仁核内的细胞体中加速了神经原纤维缠结的产生。 诱导的神经原纤维缠结发生早于Abeta42注射后18天，并显示出几种人类神经变性疾病，特别是阿尔茨海默病的神经原纤维缠结的显着特征。

公开(公告)号：USD998609S1

公开(公告)日：2023-09-12

申请号：US29887604

申请日：2023-03-22

申请人： Feng Chen

设计人： Feng Chen

摘要： FIG. 1 is a front, top perspective view of a switch portable dock showing my new design.
FIG. 2 is a front view thereof;
FIG. 3 is a rear view thereof;
FIG. 4 is a left side view thereof;
FIG. 5 is a right side view thereof;
FIG. 6 is a top view thereof;
FIG. 7 is a bottom view thereof;
FIG. 8 is a rear, bottom perspective view; and,
FIG. 9 is a front perspective view thereof, showing the switch portable dock in an open state of use.
The broken lines in the drawings depict portions of the switch portable dock that form no part of the claimed design.

公开(公告)号：US11265438B2

公开(公告)日：2022-03-01

申请号：US16978593

申请日：2018-04-26

申请人： Hewlett-Packard Development Company, L.P. ,  Da Peng Li ,  Zhi Wen Xing ,  Feng Chen

发明人： Da Peng Li ,  Zhi Wen Xing ,  Feng Chen

IPC分类号： H04N1/00 ,  H04N1/10 ,  G06F3/12

摘要： An example device includes a U-shaped body to be placed around a guide on which a scanner carriage is to be guided. A fixed leg of the U-shaped body is attached to a linearly translatable scanner carriage. A free leg of the U-shaped body is not attached to the scanner carriage and has inward facing ribs. The ribs on the free leg of the U-shaped body are positioned to come into contact with the guide to align the scanner carriage with the guide.

公开(公告)号：US10819535B2

公开(公告)日：2020-10-27

申请号：US16217556

申请日：2018-12-12

申请人： Feng Chen ,  Franz-Josef Götz ,  Marcel Kießling ,  An Ninh Nguyen ,  Jürgen Schmitt

发明人： Feng Chen ,  Franz-Josef Götz ,  Marcel Kießling ,  An Ninh Nguyen ,  Jürgen Schmitt

IPC分类号： G06F15/173 ,  H04L12/40 ,  H04L12/46 ,  H04L12/721 ,  H04L12/891 ,  H04L12/841 ,  H04L12/801 ,  H04L12/931

摘要： Methods and systems are provided for improved data packet transmission in a network bridge. Separate data packets received from a plurality of automation components are aggregated into a single data packet stream. The data packet stream is transmitted to another network node, for example, another network bridge.